


Calyx has divested its 'Enterprise Technology' Division to Ennov, to Enhance Ennov's portfolio of eClinical and eRegulatory Software Solutions



The pharmaceutical industry is experiencing a profound increase in demand for eClinical and eRegulatory solutions, driven by a mounting backlog of drugs in development. With clinical trials becoming more intricate and regulatory scrutiny intensifying, software-based tools are essential for streamlining processes. These solutions are indispensable in addressing the industry's need for agility and innovation, offering a more collaborative and accelerated approach to drug development. In the face of evolving challenges, the adoption of eClinical and eRegulatory solutions emerges as a pivotal strategy for navigating the complexities and ensuring timely submissions, ultimately facilitating faster time-to-market for pharmaceutical products. The global market for eClinical solutions is [poised to reach \\$17.9 billion by 2027](#).

Including the time prior to spinning out of Parexel,

Calyx's solutions have been used in the clinical development of over 650 approved medical treatments (70 of which received a Breakthrough Therapy designation). Their industry leading clinical development and commercialization technologies and impressive blue-chip customer base positioned Calyx's 'Enterprise Technology' division as the preferred partner for Ennov to enrich their already impressive eClinical and eRegulatory portfolio offering.

Crosstree's extensive experience in pharma services and pharma technology played a pivotal role in helping Calyx carve out its 'Enterprise Technology' division (including its RIM, EDC, and CTMS technology platforms) and identify Ennov as the optimal partner for this transaction. This will allow Ennov to expand its global footprint and bolster its ability to offer compliance management solutions to the life sciences industry.

Crosstree's specialized expertise in the healthcare technology industry enables us to deliver outcomes for our clients that go beyond exceptional.

ABOUT CALYX

CALYX™

Through innovative eClinical solutions and services, Calyx turns the uncertain into the reliable, helping bring new medical treatments to market faster. With deep expertise in clinical development and more than 25 years of supporting trial sponsors and clinical research organizations (CROs), Calyx harnesses that intelligence and activates its potential to solve complex problems, deliver fast insights, and get new drugs to market every day.

ABOUT ENNOV



Ennov provides a comprehensive software platform to manage the most demanding processes of life sciences organizations in a compliant and efficient way. With over 20 years of experience, Ennov's cloud-based solutions cover Regulatory Affairs, Pharmacovigilance, Quality, Clinical, and Document Management. Dedicated to innovation and excellence, Ennov's solutions are used by more than 500 companies and 150,000 users worldwide, helping them to bring their products to market faster while maintaining compliance with regulatory requirements.

CROSSTREE'S EXPERTS ARE SPECIALISTS IN THE NUANCES OF HEALTH SCIENCE AND PROVIDE:

- Deep analytics of capabilities and gaps
- Systemized tactical strategies and a road map to success
- Engaged experts in market analysis, financials, and premium valuations
- Targeted and qualified prospects
- Up-to-date industry trend analysis and forecasting

All while prioritizing corporate core values.

MEETING THE NEEDS OF BOTH THE BUYER AND THE SELLER - BY THE NUMBERS AND BEYOND - IS CROSSTREE'S SPECIALTY.

Crosstree's **proven track record** of superior outcomes is the result of balanced, hands-on guidance from start to close. Partner with the leading health science experts today.



JASON LAYTON

Managing Director

jason.layton@crosstreecapital.com

813-578-7109